Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, has finalized a material transfer agreement with Celgene Cellular Therapeutics. As part of the agreement, ImmuneRegen will ship its potential therapeutic Homspera to CCT for testing.
Subscribe to our email newsletter
Celgene Cellular Therapeutics (CCT) will perform testing of Homspera in order to evaluate the potential impact on cellular products in the company’s development pipeline. ImmuneRegen believes that Homspera will modify stem/progenitor cell activity which would be of value in multiple therapeutic applications of interest to both companies.
ImmuneRegen and Celgene have also agreed to explore other opportunities which may lead to complementary product development pipelines. Both the companies are exploring opportunities to jointly pursue US government funding in support of their rapid wound healing applications.